|
Date: Feb 10, 2012
By:
Formulary staff
| Source: Formulary News Capsules
Researchers are warning pediatricians, pediatric hospitalists and intensivists of the potential for intravenous acetaminophen dosing errors, especially in young patients under 2 years old.
Date: Feb 10, 2012
By:
Formulary staff
| Source: Formulary News Capsules
FDA approved axitinib (Inlyta, Pfizer) to treat patients with an advanced kidney cancer called renal cell carcinoma who have not responded to another drug for this type of cancer.
Date: Feb 10, 2012
By:
Formulary staff
| Source: Formulary News Capsules
Nursing home residents with dementia who use average doses of selective serotonin reuptake inhibitors (SSRIs) are three times more likely to have a fall resulting in injury compared with those who don’t use SSRIs, according a study published online January 18 in the British Journal of Clinical Pharmacology
Date: Feb 10, 2012
By:
Formulary staff
| Source: Formulary News Capsules
FDA declined approval of the diabetes drug dapagliflozin (Bristol-Myers Squibb and AstraZeneca), based on the recommendations of one of its advisory committees.
Date: Feb 10, 2012
By:
Formulary staff
| Source: Formulary News Capsules
There was an increased risk of acute infection among long-term care residents who visited hospital emergency departments, according to a study published online January 23 in the Canadian Medical Association Journal.
Date: Feb 10, 2012
By:
Formulary staff
| Source: Formulary News Capsules
FDA has approved linagliptin/metformin hydrochloride (Jentadueto, Boehringer Ingelheim and Eli Lilly) tablets, a new tablet that provides a single-tablet treatment option, taken twice-daily, for adult patients who need to control their blood sugar.
Date: Feb 10, 2012
By:
Formulary staff
| Source: Formulary News Capsules
An FDA advisory panel recommended against using denosumab (Xgeva, Amgen) to delay or prevent the spread of castration-resistant prostate cancer at risk for bone metastases.
Date: Feb 8, 2012
| Source: Urology Times eNews
The FDA has approved the oral kinase inhibitor axitinib (Inlyta) for the treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy.
Date: Feb 8, 2012
| Source: Urology Times eNews
The 5-alpha-reductase inhibitor dutasteride (Avodart) appears to delay disease progression and the initiation of active treatment in men with low-risk, localized prostate cancer, results of a 3-year international clinical trial indicate.
|
| 
Clinical Pharmacology
Practice Tools
